Ovarian cancer (OC) remains a fatal malignancy because most patients experience
recurrent disease, which is resistant to chemotherapy. The outcomes for patients with …

Advanced and recurrent gynecological cancers are associated with poor prognosis and lack
of effective treatment. The developments of the molecular mechanisms on cancer …

Simple Summary A major theory of cancer development is that cancer originates from a
specialised type of tumour cell called the cancer stem cell (CSC). Although CSCs comprise …

Ovarian cancer is the most lethal gynecological malignancy due to its late detection and
high recurrence rate. Resistance to conventional platinum-based therapies and metastasis …

The tumor suppressor p53 maintains an equilibrium between self-renewal and
differentiation to sustain a limited repertoire of stem cells for proper development and …

The CD133 cell membrane glycoprotein, also termed prominin-1, is expressed on some of
the tumor cells of both solid and blood malignancies. The CD133-positive tumor cells were …

Drugs targeting the DNA damage response (DDR) are widely used in cancer therapy, but
resistance to these drugs remains a major clinical challenge. Here, we show that SYCP2, a …

Ovarian cancer typically presents at an advanced stage, and although the majority of cases
initially respond well to platinum-based therapies, chemoresistance almost always occurs …

Ovarian cancer is the most lethal of all the gynecological tumors despite remarkable
advances in our understanding of its molecular biology. The cornerstone treatment remains …

Ovarian cancer (OC) is one of the most lethal gynecologic malignancies. Due to the lack of
specific symptoms and screening methods, this disease is usually diagnosed only at an …